Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;11(4):580-589.
doi: 10.1007/s12975-019-00743-6. Epub 2019 Oct 24.

Moyamoya Disease and Spectrums of RNF213 Vasculopathy

Affiliations
Review

Moyamoya Disease and Spectrums of RNF213 Vasculopathy

Oh Young Bang et al. Transl Stroke Res. 2020 Aug.

Abstract

Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive stenosis of large intracranial arteries and a hazy network of basal collaterals called moyamoya vessels. A polymorphism (R4810K) in the Ring Finger Protein 213 (RNF213) gene, at chromosome 17q25.3, is the strongest genetic susceptibility factor for MMD in East Asian populations. MMD was regarded prevalent in childhood and in East Asian populations. However, the so-called MMD could represent only the tip of the iceberg. MMD is increasingly reported in adult patients and in Western populations. Moreover, the RNF213 variant was recently reported to be associated with non-MMD disorders, such as intracranial atherosclerosis and systemic vasculopathy (e.g., peripheral pulmonary artery stenosis and renal artery stenosis). In this review, we summarize the spectrums of RNF213 vasculopathy in terms of clinical and genetic phenotypes. Continuous efforts are required for pathophysiology-based diagnoses and treatment, which will benefit from collaboration between clinicians and researchers, and between stroke and vascular physicians.

Keywords: Moyamoya disease; Polymorphism; RNF213; Vasculopathy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Roach ES, Golomb MR, Adams R, Biller J, Daniels S, Deveber G, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke. 2008;39(9):2644–91. https://doi.org/10.1161/STROKEAHA.108.189696 . - DOI - PubMed
    1. Bang OY, Ryoo S, Kim SJ, Yoon CH, Cha J, Yeon JY, et al. Adult moyamoya disease: a burden of intracranial stenosis in East Asians? PLoS One. 2015;10(6):e0130663. https://doi.org/10.1371/journal.pone.0130663 . - DOI - PubMed - PMC
    1. Chung JW, Kim SJ, Bang OY, Kim KH, Ki CS, Jeon P, et al. Determinants of basal collaterals in moyamoya disease: clinical and genetic factors. Eur Neurol. 2016;75(3-4):178–85. https://doi.org/10.1159/000445348 . - DOI - PubMed
    1. Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry. 2008;79(8):900–4. https://doi.org/10.1136/jnnp.2007.130666 . - DOI - PubMed
    1. Bang OY, Toyoda K, Arenillas JF, Liu L, Kim JS. Intracranial large artery disease of non-atherosclerotic origin: recent progress and clinical implications. J Stroke. 2018;20(2):208–17. https://doi.org/10.5853/jos.2018.00150 . - DOI - PubMed - PMC

MeSH terms

Substances

LinkOut - more resources